查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997393

新生儿筛检市场：依技术、检测类型、检体类型和最终用户划分－2026-2032年全球市场预测

Newborn Screening Market by Technology, Test Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，新生儿筛检市场价值将达到 9.8243 亿美元，到 2026 年将成长至 10.7232 亿美元，到 2032 年将达到 19.9738 亿美元，年复合成长率为 10.66%。

主要市场统计数据
基准年 2025 9.8243亿美元
预计年份：2026年 1,072,320,000 美元
预测年份 2032 1,997,380,000 美元
复合年增长率 (%) 10.66%

对技术融合、临床重点和营运限制如何重塑新生儿筛检计画进行全面的背景概述。

新生儿筛检在儿童预防医学中发挥着至关重要的作用，它能够早期发现可能导致终身严重后果的先天性疾病。近年来，诊断方法已从单一参数检测发展到利用多参数检测平台和基因组分析的工作流程，这迫使临床医生、实验室技术人员和政策制定者重新思考筛检路径和基础设施。因此，相关人员必须在临床敏感性和特异性与操作可行性、检体管理以及不断增长的基因组数据相关的伦理考量之间取得平衡。

对正在重新定义新生儿筛检服务模式的技术、资料管治和相关人员合作方面的广泛转变进行策略分析。

新生儿筛检领域正经历一场变革，主要得益于分析平台、生物资讯学以及相关人员期望的快速发展。高解析度技术，例​​如串联式质谱质谱和次世代定序，拓展了诊断能力，使得过去常规检测难以发现的代谢和遗传性疾病得以早期发现。同时，免疫检测灵敏度的提高和分子检测技术的进步缩短了结果报告时间，并优化了确诊流程，使筛检结果在新生儿护理中更具实用价值。

对近期关税变化和贸易政策转变如何影响新生儿筛检的供应连续性、筹资策略和营运韧性进行基于证据的评估。

全球贸易环境中的政策调整和关税措施可能会对整个新生儿筛检系统产生连锁反应，影响诊断设备、耗材和试剂的供应和成本结构。进口关税的提高可能导致检查室和医疗机构的采购週期延长、单位成本上升，对其营运预算和筹资策略造成压力。为此，一些机构可能会优先考虑供应商多元化、寻找本地生产合作伙伴或重新协商服务合同，以维持检测服务的连续性。

以细分为主导的综合分析，解释了技术选择、测试组合、最终用户工作流程和检体模式如何相互作用，从而确定实施路径和操作设计。

细分市场洞察揭示了临床需求、技术能力和终端使用者工作流程的交集，从而塑造了产品开发和服务交付的策略重点。在各种技术模式中，高效液相层析(HPLC) 持续发挥独特的分析作用，而免疫检测平台则可实现蛋白质生物标记的高通量筛检。包括聚合酵素链锁反应(PCR) 和桑格定序在内的分子技术能够实现标靶且快速的基因鑑定。次世代定序(NGS) 可建构更广泛的基因组panel并应用于药物发现。串联式质谱质谱仍然是多参数代谢筛检的核心。综上所述，这些技术构成了一个多层次的诊断架构，其中快速且低成本的筛检可引导使用者进行一系列更具特异性的分子或基因组确认检测。

从本地观点探讨区域政策、基础设施成熟度和供应链本地化如何影响新生儿筛检计画的设计和永续性。

区域趋势对新生儿筛检计画的设计、监管预期和供应链韧性有显着影响。在美洲，公共卫生计画通常强调标准化筛检方案，并辅以集中式检查室网路和公私混合医疗服务模式，从而促进规模经济和大量筹资策略。政策和投资的转型转变促使人们对更多基因组相关检测和试验计画产生兴趣，但相关人员必须在扩大筛选范围的同时兼顾公平性和后续照护基础设施。

策略性地整合以互通性、证据产生、策略伙伴关係和卓越服务为重点的竞争行动，以推动新生儿筛检供应商的市场格局。

产业参与者之间的竞争动态呈现出技术差异化、策略伙伴关係以及专注于服务和支援以满足临床和检查室需求的趋势。领先的仪器製造商致力于透过工作流程自动化增强平台互通性并缩短结果出具时间，而试剂供应商则优先考虑批间一致性和符合法规要求的文檔，以支援认证要求。同时，实验室服务供应商和参考网路致力于扩展其确诊检测能力并制定标准化诊疗路径，以最大限度地缩短从诊断到开始治疗的时间。

领导者必须应对的策略挑战，才能将筛检的进步转化为临床成果：加速部署、确保供应弹性、建立品质架构。

产业领导者需要采取行动，将技术潜力转化为营运和临床成果，同时应对复杂的政策和供应链问题。首先，应投资于可互通的检查室资讯系统和标准化报告格式，以确保筛检结果无缝整合到电子健康记录和人群健康登记系统中，从而增强后续工作的连续性和结果评估的准确性。其次，应优先发展人力资源，透过资助实务培训、远端支援和能力评估，确保检查室和临床医生能够应用不断发展的检测方法并解读复杂的基因检测观察。

透过文献整合、专家对话和迭代检验，我们透过透明、多方面的调查方法，确保对新生儿筛检提供稳健且实用的见解。

本研究途径结合了系统性的二手文献综述、与领域专家的有针对性的一手访谈以及严谨的资料三角验证，从而确保研究结果的有效性和实用性。首先，调查方法整合了同行评审文献、监管指导文件、技术白皮书和会议论文集，以了解当前的技术现状、临床指南和操作实践。这为识别关键主题和知识缺口奠定了基础，这些主题和缺口需要透过一手研究进行深入探讨。

简洁扼要的总结强调，需要协调技术创新、营运基础设施和公平的专案设计，以最大限度地发挥新生儿筛检的益处。

总之，新生儿筛检正处于转折点，分析技术、数据整合和策略合作的创新有望显着提高儿童的早期检出率和长期预后。从串联式质谱质谱和高效液相层析到标靶分子检测和全基因测序，各项技术进步提供了互补的功能，可供检查室和医疗系统在逐步筛检流程中加以利用。然而，要真正实现临床获益，营运框架、监管合规性以及跨地区和医疗机构的公平取得至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：新生儿筛检市场：依技术划分

  • 高效液相层析
  • 免疫检测
  • 分子技术
    • 聚合酵素链锁反应
    • 桑格法
  • 次世代定序
  • 串联式质谱质谱法

第九章：新生儿筛检市场（依检测类型划分）

  • 囊肿纤维化
  • 内分泌疾病
  • 血红素异常
  • 先天性代谢缺陷

第十章新生儿筛检市场（检体类型划分）

  • 干血斑
  • 血清检体

第十一章：新生儿筛检市场：依最终用户划分

  • 诊断检查室
  • 医院和诊所
  • 研究所

第十二章：新生儿筛检市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：新生儿筛检市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：新生儿筛检市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国新生儿筛检市场

第十六章：中国新生儿筛检市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Danaher Corporation
  • MP Biomedicals LLC
  • Novartis AG
  • PerkinElmer, Inc.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
  • Waters Corporation
Product Code: MRR-501246436EC1

The Newborn Screening Market was valued at USD 982.43 million in 2025 and is projected to grow to USD 1,072.32 million in 2026, with a CAGR of 10.66%, reaching USD 1,997.38 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 982.43 million
Estimated Year [2026] USD 1,072.32 million
Forecast Year [2032] USD 1,997.38 million
CAGR (%) 10.66%

A definitive contextual overview of how technological convergence, clinical priorities, and operational constraints are reshaping newborn screening programs

Newborn screening occupies a pivotal role in preventive pediatric healthcare by enabling early detection of congenital conditions that can profoundly affect lifelong outcomes. Over recent years, the diagnostic landscape has evolved from single-analyte assays toward multiplexed platforms and genomics-enabled workflows, prompting clinicians, laboratorians, and policy makers to reassess screening pathways and infrastructure. Consequently, stakeholders must balance clinical sensitivity and specificity with operational feasibility, sample logistics, and ethical considerations surrounding expanded genomic data.

As technology converges with clinical practice, laboratory networks and end users face novel integration challenges. Dried blood spot specimens remain foundational for many programs, yet serum-based assays and molecular workflows now complement and sometimes supplant traditional approaches. This shift has practical implications for specimen collection, cold chain management where applicable, and the downstream analytics that inform diagnostic confirmation and therapeutic interventions.

Moreover, regulatory expectations and payer scrutiny increasingly emphasize outcomes and cost-effectiveness, driving demand for robust evidence generation and standardized quality frameworks. Therefore, health systems and suppliers must collaborate to optimize protocols, training, and data capture to ensure reliable population-level screening while preserving patient privacy and informed consent. Ultimately, a strategic introduction to the current state of newborn screening highlights the interplay of science, policy, and operational execution that will define next-generation programs

A strategic analysis of the sweeping technological, data governance, and stakeholder collaboration shifts that are redefining newborn screening delivery models

The newborn screening landscape is undergoing transformative shifts driven by rapid advances in analytical platforms, bioinformatics, and stakeholder expectations. High-resolution techniques such as tandem mass spectrometry and next-generation sequencing have expanded diagnostic breadth, enabling earlier identification of metabolic and genetic disorders that previously eluded routine detection. At the same time, improvements in immunoassay sensitivity and molecular assays have reduced turnaround times and improved confirmatory workflows, making screening results more actionable in neonatal care settings.

Concurrently, the integration of digital health tools and laboratory information systems has elevated data management, facilitating automated flagging, longitudinal tracking, and tighter linkage between screening and follow-up care. These developments are accompanied by increasing emphasis on harmonized quality metrics and proficiency testing, which together reinforce trust in expanded screening panels. Moreover, public health authorities and clinical networks are revisiting screening panels and consent models to accommodate genomic findings while managing ethical implications.

Finally, the rise of collaborative partnerships across instrument manufacturers, reagent suppliers, clinical laboratories, and payers supports innovation diffusion and scale-up. As a result, organizations that prioritize interoperability, scalable workflows, and clinician engagement will navigate this transformation most effectively, positioning themselves to translate technical capability into improved neonatal outcomes

An evidence-based appraisal of how recent tariff shifts and trade policy changes can influence supply continuity, procurement strategies, and operational resilience in newborn screening

Policy adjustments and tariff measures introduced in global trade environments can ripple through the newborn screening ecosystem by affecting the availability and cost structure of diagnostic instruments, consumables, and reagents. When import tariffs rise, laboratories and healthcare providers may confront longer procurement cycles and elevated unit costs for capital equipment and single-use kits, which in turn can pressure operational budgets and procurement strategies. In response, some organizations may prioritize supplier diversification, seek localized manufacturing partners, or renegotiate service contracts to preserve continuity of testing services.

At the same time, higher input costs can accelerate adoption of maintenance and lifecycle management practices that extend equipment usability and reduce downtime. For example, laboratories may intensify preventive maintenance scheduling, invest in training that broadens in-house technical capabilities, and adopt standardized consumables across testing platforms to achieve economies of scale. Additionally, procurement teams may increase emphasis on total cost of ownership analyses and multi-year supply agreements to buffer against tariff volatility.

Importantly, regulatory compliance and quality assurance requirements will continue to shape supplier selection regardless of tariff dynamics. Therefore, while policymakers and industry participants adapt to evolving trade conditions, the primary focus remains on preserving diagnostic accuracy, turnaround time, and equitable access to newborn screening. In the longer term, shifts in trade policy may incentivize reshoring of certain manufacturing capabilities and foster regional supply ecosystems that enhance resilience without compromising clinical standards

A cohesive segmentation-driven analysis explaining how technology choices, test portfolios, end-user workflows, and specimen modalities interact to determine adoption pathways and operational design

Insight into segmentation illuminates where clinical need, technological capability, and end-user workflows intersect, shaping strategic priorities for product development and service delivery. Across technology modalities, High Performance Liquid Chromatography continues to serve niche analytical roles while Immunoassay platforms provide high-throughput screening for protein biomarkers; Molecular Techniques comprising Polymerase Chain Reaction and Sanger Sequencing deliver targeted, rapid genetic confirmation; Next Generation Sequencing enables broader genomic panels and discovery applications; and Tandem Mass Spectrometry remains central for multiplex metabolic screening. Taken together, these platforms create a layered diagnostic architecture where rapid, low-cost screens feed into more specific molecular or genomic confirmatory pipelines.

Regarding test types, traditional screens for conditions such as cystic fibrosis, endocrine disorders, hemoglobinopathies, and inborn errors of metabolism maintain high clinical urgency and established care pathways. These test categories influence assay validation requirements, specimen handling protocols, and clinical follow-up algorithms. In parallel, end users across diagnostic laboratories, hospitals and clinics, and research laboratories have distinct priorities: diagnostic laboratories emphasize throughput, accreditation, and cost control; hospitals and clinics focus on clinical integration and timely result reporting; and research laboratories prioritize assay flexibility and data richness for translational studies.

Sample type considerations further shape operational design, as dried blood spot specimens support broad population screening with logistical simplicity and archival stability, while serum samples enable certain quantitative assays and confirmatory testing that require different collection and processing workflows. Consequently, vendors and laboratory managers who align platform capabilities with specific test portfolios, end-user constraints, and specimen logistics will drive adoption and clinical utility

A nuanced regional perspective on how jurisdictional policy, infrastructure maturity, and supply chain localization shape newborn screening program design and sustainability

Regional dynamics exert pronounced influence on program design, regulatory expectations, and supply chain resilience in newborn screening initiatives. In the Americas, public health programs often emphasize standardized screening panels supported by centralized laboratory networks and a mix of public and private providers, which encourages scale economies and consolidated procurement strategies. Transitional phrases in policy and investment have increased interest in genomic add-ons and pilot programs, but stakeholders must balance expansion with equity and follow-up care capacity.

Meanwhile, Europe, Middle East & Africa present heterogeneous landscapes where regulatory regimes, healthcare financing, and infrastructure maturity vary widely. In well-resourced jurisdictions, advanced analytical platforms and comprehensive confirmatory pathways are increasingly common, whereas resource-limited settings prioritize robust, low-complexity assays and training to expand basic coverage. Cross-border collaborations and capacity-building initiatives play a key role in narrowing gaps and enabling technology transfer.

Across Asia-Pacific, rapid modernization of laboratory networks and strong domestic manufacturing capabilities support accelerating adoption of advanced screening modalities. However, diverse reimbursement models and population health priorities mean that rollout strategies differ, with some economies piloting genomic integration while others focus on optimizing existing biochemical screening. Overall, regional strategy must account for regulatory harmonization, supply chain diversification, and investments in workforce development to ensure sustainable program expansion

A strategic synthesis of competitive behaviors emphasizing interoperability, evidence generation, strategic alliances, and service excellence that drive the newborn screening vendor landscape

Competitive dynamics among industry participants reflect a blend of technological differentiation, strategic partnerships, and emphasis on service and support to meet clinical and laboratory needs. Leading instrument manufacturers focus on enhancing platform interoperability and reducing time-to-result through workflow automation, while reagent suppliers prioritize lot-to-lot consistency and regulatory-compliant documentation to support accreditation requirements. In parallel, laboratory service providers and reference networks concentrate on scaling confirmatory testing capacity and developing standardized care pathways that minimize time to diagnosis and treatment initiation.

Strategic activity also includes partnerships between technology vendors and clinical networks to validate expanded panels, as well as collaborations with academic centers to refine variant interpretation frameworks and evidence generation. Furthermore, companies are directing resources toward training programs and remote support capabilities to reduce technical barriers for decentralized laboratories and to ensure consistent quality across sites. Mergers and alliances continue to shape the supplier landscape, enabling broader product portfolios and distribution reach while creating opportunities for integrated solutions that bundle instruments, consumables, software, and data services.

Collectively, these corporate strategies emphasize reliability, scalability, and regulatory alignment. Organizations that balance innovation with clear pathways for clinical validation and robust post-market support will sustain competitive advantage and foster stronger partnerships with public health programs and healthcare providers

Actionable strategic imperatives for leaders to accelerate adoption, secure supply resilience, and embed quality frameworks that translate screening advances into clinical outcomes

Industry leaders must adopt pragmatic steps to convert technological promise into operational and clinical impact while navigating policy and supply chain complexities. First, invest in interoperable laboratory informatics and standardized reporting formats to ensure that screening results integrate smoothly into electronic health records and population health registries, thereby strengthening follow-up continuity and outcome measurement. Second, prioritize workforce development by funding hands-on training, remote support, and competency assessments so that laboratories and clinicians can reliably implement evolving assays and interpret complex genetic findings.

Next, cultivate diversified supplier relationships and explore regional manufacturing or distribution partnerships to mitigate procurement disruptions and reduce exposure to trade variability. Simultaneously, embed lifecycle management practices that extend equipment uptime and align maintenance schedules with clinical demand patterns. In parallel, engage proactively with regulatory bodies and payers to co-design evidence generation studies that demonstrate clinical utility, real-world performance, and health-economic implications while addressing ethical concerns related to genomic screening.

Finally, pursue collaborative models that link vendors, laboratories, clinicians, and public health entities to pilot integrated care pathways and data-sharing initiatives. By aligning commercial strategy with clinical priorities and system-level goals, leaders can accelerate adoption, preserve diagnostic quality, and deliver measurable improvements in neonatal health outcomes

A transparent, multi-source research methodology combining literature synthesis, expert engagement, and iterative validation to ensure robust and actionable newborn screening insights

The research approach combines systematic secondary literature review, targeted primary engagement with domain experts, and rigorous data triangulation to ensure validity and applicability of insights. Initially, the methodology synthesized peer-reviewed literature, regulatory guidance documents, technical whitepapers, and conference proceedings to map the technology landscape, clinical guidelines, and operational practices. This provided a foundation for identifying key themes and knowledge gaps that warranted further investigation through primary research.

Primary engagement comprised structured interviews with laboratory directors, clinical geneticists, procurement specialists, and public health officials to capture real-world implementation experiences, pain points, and strategic priorities. In addition, vendor discussions explored product roadmaps, validation practices, and service models. Responses were anonymized and cross-checked to avoid bias and to ensure that conclusions reflect consensus where possible and divergent views where appropriate.

Finally, iterative triangulation reconciled qualitative insights with documented evidence, and quality controls included validation of technical descriptions by subject-matter experts and consistency checks across data sources. The methodology emphasized transparency by documenting inclusion and exclusion criteria, interview protocols, and validation steps to support reproducibility and to facilitate informed use of the report's findings

A concise synthesis underscoring the imperative to align technological innovation, operational readiness, and equitable program design to unlock newborn screening benefits

In conclusion, the newborn screening landscape stands at an inflection point where analytical innovation, data integration, and strategic collaboration can materially improve early detection and long-term outcomes for affected infants. Technological advances-from tandem mass spectrometry and high-performance chromatography to targeted molecular assays and broader genomic sequencing-offer complementary capabilities that laboratories and health systems can deploy in layered screening pathways. Yet, realizing clinical benefit depends on operational readiness, regulatory alignment, and equitable access across regions and care settings.

Moving forward, stakeholders must prioritize interoperability, workforce capacity, and evidence-based engagement with regulatory and payer entities to ensure that expanded screening delivers measurable health improvements without compromising quality or exacerbating disparities. Supply chain resilience and procurement agility remain essential as trade dynamics and policy shifts influence access to instruments and consumables. By focusing on pragmatic measures-such as diversified sourcing, lifecycle maintenance, standardized reporting, and collaborative validation-organizations can mitigate risk while advancing programmatic goals.

Ultimately, the combination of clinical need, technological opportunity, and system-level commitment creates a window for meaningful progress in newborn screening. Stakeholders who align strategy with operational execution and patient-centered outcomes will be best positioned to translate innovation into enduring public health impact

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Newborn Screening Market, by Technology

  • 8.1. High Performance Liquid Chromatography
  • 8.2. Immunoassay
  • 8.3. Molecular Techniques
    • 8.3.1. Polymerase Chain Reaction
    • 8.3.2. Sanger Sequencing
  • 8.4. Next Generation Sequencing
  • 8.5. Tandem Mass Spectrometry

9. Newborn Screening Market, by Test Type

  • 9.1. Cystic Fibrosis
  • 9.2. Endocrine Disorders
  • 9.3. Hemoglobin Disorders
  • 9.4. Inborn Errors Of Metabolism

10. Newborn Screening Market, by Sample Type

  • 10.1. Dried Blood Spot
  • 10.2. Serum Sample

11. Newborn Screening Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Laboratories

12. Newborn Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Newborn Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Newborn Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Newborn Screening Market

16. China Newborn Screening Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Agilent Technologies, Inc.
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. BioMerieux SA
  • 17.9. Danaher Corporation
  • 17.10. MP Biomedicals LLC
  • 17.11. Novartis AG
  • 17.12. PerkinElmer, Inc.
  • 17.13. Shimadzu Corporation
  • 17.14. Siemens Healthineers AG
  • 17.15. Thermo Fisher Scientific Inc.
  • 17.16. Trivitron Healthcare
  • 17.17. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEWBORN SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEWBORN SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEWBORN SCREENING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEWBORN SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEWBORN SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEWBORN SCREENING MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEWBORN SCREENING MARKET SIZE, BY ENDOCRINE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HEMOGLOBIN DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEWBORN SCREENING MARKET SIZE, BY INBORN ERRORS OF METABOLISM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEWBORN SCREENING MARKET SIZE, BY SERUM SAMPLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEWBORN SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEWBORN SCREENING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEWBORN SCREENING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GCC NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 114. GCC NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. G7 NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. G7 NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 132. G7 NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. G7 NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. NATO NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. NATO NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 138. NATO NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA NEWBORN SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA NEWBORN SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA NEWBORN SCREENING MARKET SIZE, BY MOLECULAR TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA NEWBORN SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA NEWBORN SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA NEWBORN SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)